Advanced Search

 

Study ID Status Title Patient Level Data
113376 Completed A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
113377 Completed Phase I study of GSK573719 -A randomized, double blind, placebo controlled, dose ascending, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 from a novel dry powder device in healthy Japanese male subjects Study Listed on ClinicalStudyDataRequest.com
113388 Terminated RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures (>= 12 years old) and Subjects with Lennox-Gastaut Syndrome (>=12 years old) Study Listed on ClinicalStudyDataRequest.com
113398 Completed Consistency of immunogenicity and non inferiority of three production lots of GSK Biologicals’ candidate malaria vaccine in children Study Listed on ClinicalStudyDataRequest.com
113412 Completed An open-label single dose randomized, parallel group study followed by single-blind repeat dosing, to compare the relative bioavailability of GSK2212836 Study Listed on ClinicalStudyDataRequest.com
113434 Completed A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis Study Listed on ClinicalStudyDataRequest.com
113435 Completed A randomised, double-blind (for GW870086), placebo-controlled study of topical GW870086 formulation to explore the potential for skin thinning in healthy adult volunteers Study Listed on ClinicalStudyDataRequest.com
113440 Completed A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340273A and GSK2340274A in adults aged 18 years and older Study Listed on ClinicalStudyDataRequest.com
113456 Completed Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years Study Listed on ClinicalStudyDataRequest.com
113459 Completed Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above Study Listed on ClinicalStudyDataRequest.com
113462 Completed Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 6 to 35 months Study Listed on ClinicalStudyDataRequest.com
113463 Completed An Open-Label Study to Characterize the Absorption, Distribution, Metabolism and Elimination of a Single Oral 14C Labeled Dose of GSK2118436 in Subjects with BRAF Mutant Solid Tumors
113468 Completed An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects with BRAF Mutation-Positive Tumor
113477 Completed An open-label, randomised, two-way crossover study, to evaluate and compare the pharmacokinetics of fluticasone furoate, administered from a novel dry powder device (repeat dose) and intravenously (single dose), in healthy Caucasian, Japanese, Korean and Chinese subjects Study Listed on ClinicalStudyDataRequest.com
113479 Completed Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered with an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects with BRAF Mutant Solid Tumors
113480 Completed A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in adults aged 18 years and older Study Listed on ClinicalStudyDataRequest.com
113482 Completed A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age Study Listed on ClinicalStudyDataRequest.com
113483 Completed A study to evaluate immune responses following A/California/7/2009 (H1N1)v-like virus vaccination given 4 months following seasonal influenza vaccination in adults 19 to 40 years of age Study Listed on ClinicalStudyDataRequest.com
113492 Completed Balanced cohort study of thiazolidinediones (TZDs) and other antidiabetic therapies and coronary heart disease events
113492_1 Completed Balanced cohort study of thiazolidinediones (TZDs) and other antidiabetic therapies and coronary heart disease events
113492_2 Completed Balanced cohort study of thiazolidinediones (TZDs) and other antidiabetic therapies and coronary heart disease events
113505 Completed Coronary heart disease outcomes in patients receiving antidiabetic therapy
113505_1 Completed Thiazolidinediones and coronary heart disease in a US health insurance database
113506 Completed A study to investigate the interaction of GSK1292263 with rosuvastatin and simvastatin in healthy subjects Study Listed on ClinicalStudyDataRequest.com
113518 Completed Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.